Tetherex Pharmaceuticals Signs Exclusive Worldwide License with Mayo Clinic for Development and Commercialization of a Novel Single-Cycle Adenovirus Vaccine Platform
OKLAHOMA CITY, July 6,2021 /PRNewswire/ --Tetherex Pharmaceuticals, Inc., a privately held, clinical stage biopharmaceutical company developing novel selectin inhibitor products to treat inflammatory diseases, today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
- OKLAHOMA CITY, July 6,2021 /PRNewswire/ --Tetherex Pharmaceuticals, Inc., a privately held, clinical stage biopharmaceutical company developing novel selectin inhibitor products to treat inflammatory diseases, today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
- The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19.
- The single-cycle adenovirus platform was developed to enhance the expression of target antigens, amplifying immune responses to infectious disease targets.
- Preclinical studies have demonstrated that the single-cycle adenovirus can markedly increase target antigen expression over that of currently utilized replication defective adenovirus vaccines.